Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)

NCT02615938 is registered in ClinicalTrials.gov with Matthias Griese as lead sponsor.

NCT NCT02615938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02615938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)
Lead sponsor
Matthias Griese
Phase
Phase 2
Overall status
Terminated
Start date
August 21, 2015
Completion date
September 9, 2020
Enrollment
35 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

children´s interstitial lung disease, diffuse parenchymal lung disease, interstitial lung disease